Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  SANOFI    SAN   FR0000120578

SANOFI (SAN)

2467
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

10/08/2012 | 01:44am US/Eastern
Recommend:
0

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at inti.landauro@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
Recommend :
0
React to this article
Latest news on SANOFI
1d ago SANOFI : Genzyme : Announces Winners of Patient Advocacy Leadership (PAL) Awards
1d ago APOLLO HOSPITALS ENTERPRISE : Sanofi to work on diabetes care
1d ago Plant-based vaccines challenge big pharma for $3 billion flu market
2d ago REGENERON PHARMACEUTICALS : Sanofi say sinusitis drug met goals
2d ago GENZYME : Dr. Alan E. Smith, Former Chief Scientific Officer of Genzyme, Joins I..
2d ago GENZYME : The CMTA Links with Genzyme to Discover Therapy for Hereditary Neuropa..
2d ago SANOFI : and Regeneron Announce Positive Phase 2 Top-line Dupilumab Results in P..
2d ago SANOFI : Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Resul..
3d ago GENZYME : Collaborates on Gene Therapy for Rare Disease that Causes Childhood Bl..
5d ago SANOFI : European Pharmaceutical Trade Body EFPIA Affirms Strengthened Commitmen..
Advertisement
Chart
Duration : Period :
SANOFI Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF